How can care providers ensure cancer survivors continue to receive adequate follow-up care post treatment?
Joseph Alvarnas, MD, asked the panels opinion on what they perceive as opportunities for improving survivorship care. "What do you see as the gaps in survivorship care? You mentioned some of them earlier. What are they and how do we get towards this idea of really preparing patients for their life after cancer?" he asked.
In response, Rebekkah Schear, MIA, shared results of a LIVESTRONG survey from several years ago that found that a majority of patients had at least 1 posttreatment physical, emotional, or practical concern. However, 29% said they did not receive care for their physical concerns, nearly 50% voiced lack of follow-up care for their emotional concerns, and one-third did not get follow-up care for practical concerns. Less than half of the patients reported having conversations on fertility preservation and fertility risk with their provider. "I think that across the board we're seeing the needle begin to move a little bit in terms of survivorship evolving as a movement," Schear said.
Lending his experience as an oncologist to the discussion, Michael Kolodziej, MD, said that a lot remains unknown with chemotherapy agents. He cited examples of patients with breast cancer whom he had treated about 2 decades ago and who were concerned about cardiac effects post treatment with Adriamycin or Herceptin—drugs known to be cardiotoxic. He said he was at a loss for information because not much was known back then about survivorship care. In his opinion, primary care providers need to play a much bigger role in caring for patients who have survived a cancer diagnosis and treatment.
"If we can start to develop the evidence base that will allow us to give good recommendations to our patients and to our primary care physician colleagues, we'll actually improve the life and promote the wellness of our patients for a long, long time," Kolodziej said.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More